| Literature DB >> 22952593 |
Siriluck Ponsuksili1, Eduard Murani, Manfred Schwerin, Karl Schellander, Dawit Tesfaye, Klaus Wimmers.
Abstract
Embryonic implantation to establish a pregnancy is a complex process that requires appropriate communication between the embryo and the maternal endometrium. Inadequate uterine receptivity may contribute to the majority of implantation failures. To provide a comprehensive inventory of genes and functional networks that represent the maternal input of the embryo-maternal cross-talk, a longitudinal, holistic study of the endometrial transcriptome in relation to the days of estrous and to the receptivity of the endometrium was performed in bovine. At day 3 of estrous, genes related to cell communication and mitochondrial energy metabolism were differentially expressed among high- and low-receptive endometria (HR, LR); at day 7, transcripts functioning in immune and inflammatory pathways, oxidative stress, and angiogenesis had different abundances. Additionally, temporal transcriptional changes between days 3 and 7 differed considerably among HR and LR. Further, several transcription factors were predicted as relevant for receptivity because they were either differentially expressed among HR and LR animals or are known to be associated with genes we detected to have differential expression. Finally, global DNA methylation varied according to the interaction of receptivity group and day of estrous, and a divergent trend, which correlated with abundance of DNMT1 transcript, was observed in LR and HR along the estrous cycle days. The study revealed that, even in early estrous, transcripts related to cell communication and response to exogenous stimuli, vascularization, and energy supply show divergent expression and longitudinal temporal regulation in HR and LR. Key components of these molecular pathways are known to be dependent on ovarian hormones that promote uterine receptivity.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22952593 PMCID: PMC3428322 DOI: 10.1371/journal.pone.0042402
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Number of regulated probe-sets in the endometrial biopsies.
The numbers at the horizontal arrows indicate the quantity of probe-sets significantly regulated between the adjacent stages within either the HR or the LR group, whereas the numbers in the intersections indicate the quantity of probe-sets commonly regulated between day 3 to day 7 (↑ = higher transcript abundance at day 3, ↓ = lower transcript abundance at day 3) in both the HR and the LR group. The numbers at vertical arrows are the number of probe-sets differentially expressed between HR and LR at the same day of estrous cycle (↑ = higher transcript abundance in the HR groups, ↓ = lower transcript abundance in the HR groups).
Molecular and cellular functions of transcripts with different abundance in the HR and LR groups at day 3 of the estrous cycle.
| No. of genes | p-values | |
|
| ||
|
| ||
| Molecular Transport | 65 | 4.41E-06-1.71E-02 |
| Cellular Assembly and Organization | 66 | 4.97E-06-1.71E-02 |
| Cell Cycle | 48 | 3.98E-05-1.71E-02 |
|
| ||
| Integrin Signaling | 12 | 1.69E-04 |
| Actin Cytoskeleton Signaling | 12 | 3.17E-04 |
| Rac Signaling | 8 | 4.18E-04 |
|
| ||
|
| ||
| Cellular Assembly and Organization | 21 | 2.93E-05-4.73E-02 |
| Cellular Function and Maintenance | 21 | 2.93E-05-4.73E-02 |
| Energy Production | 7 | 1.22E-03-4.45E-02 |
|
| ||
| Mitochondrial Dysfunction | 7 | 2.35E-04 |
| Ubiquinone Biosynthesis | 5 | 4.25E-04 |
| Oxidative Phosphorylation | 6 | 2.05E-03 |
Figure 2Canonical pathways enriched for transcripts showing different abundance depending on receptivity group and day of estrous cycle.
Pathways showing temporal regulation from day 3 to day 7 are given at the horizontal vectors of either the HR (top part) or the LR group (lower part) (↑ = higher transcript abundance at day 3, ↓ = lower transcript abundance at day 3). Pathways of transcript showing different abundance among the Hr and LR at day 3 (left) or day 7 od estrous cycle are displayed at the vertical vectors (↑ = higher transcript abundance in the HR groups, ↓ = lower transcript abundance in the HR groups).
Molecular and cellular functions of transcripts with different abundance in the HR and LR groups at day 7 of the estrous cycle.
| No. of genes | p-values | |
|
| ||
|
| ||
| Cellular Development | 78 | 4.15E-09-5.44E-03 |
| Cellular Movement | 57 | 9.9E-09-5.47E-03 |
| Cellular Growth and Proliferation | 86 | 9.98E-07-5.44E-03 |
|
| ||
| T Cell and B Cell Signaling | 7 | 9.67E-05 |
| NF-êB Signaling | 7 | 5.07E-03 |
| Inositol Phosphate Metabolism | 6 | 7.58E-03 |
|
| ||
|
| ||
| Cellular Assembly and Organization | 18 | 7.06E-07-4.99E-02 |
| Cellular Function and Maintenance | 20 | 5.08E-06-4.84E-02 |
| Cell Death | 29 | 5.06E-04-4.84E-02 |
|
| ||
| Inhibition of Angiogenesis | 3 | 1.75E-03 |
| NRF2-mediated Oxidative Stress Response | 4 | 3.87E-02 |
Molecular and cellular functions of transcripts with different changes of abundance between day 3 and day 7 of the estrous cycle in the HR groups.
| No. of genes | p-values | |
|
| ||
|
| ||
| Carbohydrate Metabolism | 6 | 3.70E-05-2.39E-02 |
| Lipid Metabolism | 10 | 3.70E-05-2.93E-02 |
| Small Molecule Biochemistry | 22 | 3.70E-05-2.39E-02 |
| Gene Expression | 90 | 8.16E-05-2.36E-02 |
| cellular assembly and organization | 65 | 1.31E-04-2.39E-02 |
|
| ||
| Role of BRCA1 in DNA Damage Response | 9 | 6.61E-06 |
| Hereditary Breast Cancer Signaling | 11 | 1.15E-04 |
| ATM Signaling | 7 | 2.26E-04 |
| Role of CHK Proteins in Cell Cycle Checkpoint Control | 5 | 1.058E-03 |
|
| ||
|
| ||
| cellular movement | 68 | 2.44E-10-4.35E-03 |
| cell-to-cell signaling and interaction | 57 | 5.20E-08-4.35E-03 |
| cell death | 93 | 1.68E-07-4.23E-03 |
| Antigen Presentation | 33 | 2.24E-07-2.89E-03 |
| Cellular Function and Maintenance | 30 | 7.86E-07-4.23E-03 |
|
| ||
| TREM1 Signaling | 6 | 3.19E-04 |
| Graft-versus-Host Disease Signaling | 5 | 1.12E-03 |
| Coagulation system | 4 | 2.96E-03 |
| Glutathione Metabolism | 5 | 3.95E-03 |
Molecular and cellular functions of transcripts with different changes of abundance between day 3 and day 7 of the estrous cycle in the LR groups.
| No. of genes | p-values | |
|
| ||
|
| ||
| Gene Expression | 98 | 2.40E-05-5.48E-03 |
| Cellular Growth and Proliferation | 113 | 3.45E-07-1.61E-02 |
| Cellular Development | 98 | 1.30E-06-1.61E-02 |
| Cell cycle | 62 | 5.19E-06-1.33E-02 |
| Cell-To-Cell Signaling and Interaction | 33 | 5.19E-06-1.61E-02 |
|
| ||
| Prolactin Signaling | 7 | 6.23E-04 |
| Lysine Degradation | 6 | 1.33E-03 |
| T cell receptor signaling | 7 | 3.27E-03 |
|
| ||
|
| ||
| Gene Expression | 111 | 2.34E-08-2.48E-02 |
| RNA Post-Transcriptional Modification | 16 | 2.68E-06-7.50E-03 |
| Cellular Growth and Proliferation | 125 | 1.01E-05-2.48E-02 |
| Molecular Transport | 89 | 2.64E-05-2.48E-02 |
| Protein Synthesis | 47 | 2.82E-05-2.38E-02 |
|
| ||
| Mitochondrial Dysfunction | 14 | 6.12E-06 |
| Estrogen Receptor Signaling | 13 | 1.63E-05 |
| Actin Cytoskeleton Signaling | 14 | 8.96E-04 |
Comparison of microarray data and qRT-PCR of selected transcripts.
| qRT-PCR_individual | Array_pool | Correlation | ||||||||||||
| LSMEAN of relative expression levels and | LSMEAN of log2 expression levels and | qRT-PCR_vs_Array | ||||||||||||
| Gene | HR | LR |
| d3 | d7 |
| HR | LR |
| d3 | d7 |
| R |
|
| DDX46 | 119842.7 | 116256.6 | 0.752 | 133304.9 | 102794.3 | 0.011 | 8.6 | 8.7 | 0.394 | 8.8 | 8.5 | 0.049 | 0.636 | 0.026 |
| KRT5 | 23695.9 | 6018.3 | 0.148 | 1530.5 | 28183.8 | 0.032 | 8.4 | 6.9 | 0.006 | 6.1 | 9.2 | <.0001 | 0.899 | <.0001 |
| PTGES | 66422.5 | 53800.4 | 0.323 | 70944.1 | 49278 | 0.094 | 7.0 | 6.9 | 0.429 | 7.1 | 6.8 | 0.177 | 0.706 | 0.010 |
| PTGS2 | 7303.3 | 9972.8 | 0.646 | 2732.7 | 14543.4 | 0.048 | 7.5 | 8.0 | 0.414 | 6.4 | 9.1 | 0.002 | 0.873 | <.0001 |
| AP2S1 | 18037.3 | 16310.0 | 0.052 | 14799.2 | 19548.1 | <.0001 | 6.4 | 6.6 | 0.010 | 6.4 | 7.0 | 0.001 | 0.636 | 0.026 |
| HPGD | 6447.0 | 11289.9 | 0.059 | 3134.0 | 14602.9 | <.0001 | 8.5 | 8.8 | 0.256 | 7.8 | 9.5 | <.0001 | 0.911 | <.0001 |
| ESRRA | 7530.6 | 6428.1 | 0.078 | 5118.8 | 8839.9 | <.0001 | 7.5 | 7.2 | 0.026 | 7.2 | 7.5 | 0.006 | 0.711 | 0.010 |
| TP53 | 38298.8 | 25727.9 | <.0001 | 40947.4 | 23079.3 | <.0001 | 8.5 | 8.4 | 0.417 | 8.7 | 8.2 | 0.002 | 0.836 | <.0001 |
| PIP | 1986.9 | 2801.3 | 0.093 | 930.3 | 3858.0 | <.0001 | 7.5 | 8.3 | 0.001 | 6.8 | 8.9 | <.0001 | 0.826 | <.0001 |
| SLK | 22498.6 | 16804.0 | 0.020 | 17943.0 | 21360 | 0.153 | 7.4 | 6.8 | <.0001 | 6.8 | 7.3 | 0.004 | 0.607 | 0.036 |
| ATP1B3 | 46554.1 | 30485.9 | <.0001 | 36087.1 | 40953 | 0.245 | 6.1 | 5.5 | <.0001 | 5.6 | 6.0 | 0.004 | 0.842 | <.0001 |
Transcription factors associated with the differential transcript abundance among the experimental groups.
| comparisons | transcription factor | predicted activation state | Z-score | fold change of transcript abundance | p-value of overlap | target molecules |
| HR3>LR3 | TP53 | Activated | 2.293 | 1.46E-04 | AP3B1,APOE,APP,CDH1,COL1A1,COL4A1,CRIP2,DNASE1,EIF4G3,EPHX1, GSN,JUN,KRT8,MAP2K1,MAPK1,MED13L,MUC2,NFKBIA,P4HA1,PIK3R1, PLEKHB2,PLXNB2,PMEPA1,PPP5C,PRKAB1,PROSC,RFWD2,RHOB, STK17A,TGFBI,TIMP2,TSPAN6 | |
| HR7>LR7 | FOS | Inhibited | −2.497 | 1.39E-03 | A2M,AQP3,ATF7IP,BCAR3,CADM1,CAST,FN1,KRT13,LAMA3,MGST1, S100A8,S100A9,SELENBP1,TBL1X | |
| RELB | 1.254 | 1.69E-02 | IL1B,NOS2,RELB | |||
| PYCARD | 1.642 | 2.01E-03 | IL18,IL1B | |||
| TFAP2A | 1.972 | 3.32E-03 | ANXA1,CXCL2,CYP11A1,KRT5,SESN3 | |||
| HR7>HR3 | SATB1 | Inhibited | −2.374 | 9.67E-02 | CD69,GATA3,GPT2,SPI1 | |
| HR3>HR7 | HTT | Activated | 2.020 | 1.45E-02 | AQP1,ATP2C1,CDK2AP1,COL16A1,COL18A1,COL4A1,CSNK1E,EBF1,FHL1,GAS7,IGFBP5,JUN,MEIS2,MMP2,PER2,PPRC1,PTPN23,RAB17,SCAMP5, SERPINH1,SESN1,SETDB1,TP53,UCHL1,VIPR2 | |
| PPARA | Inhibited | −2.253 | 1.13E-01 | C3,C8A,CYP2B6,IGFBP5,PCK1 | ||
| TP53 | Activated | 2.033 | 1.459 | 1.29E-03 | ANTXR1,ASF1B,C1QC,COL18A1,COL4A1,CRIP2,CYR61,DNASE1,F2R,FHL1,GLB1,HSP90AA1,IGFBP4,IGFBP5,IGFBP7,IQCB1,JUN,LATS2,LRRC17, MAP2K4,MFAP2,MMP2,MPDZ,MSH6,PAWR,PCBP4,PIK3R1,PLXNB2, PMEPA1,PRKAB1,RAD50,RHOB,RUVBL2,SESN1,SIVA1,TFPI2,TP53,TP73 | |
| SPI1 | −1.445 | 3.32E-02 | CEBPA,CSF2RA,IL18,SPI1,TLR2,TREM1 | |||
| IRF5 | −1.396 | 2.20E-02 | CCL4,IRF5,RSAD2 | |||
| CEBPA | −1.304 | 8.07E-04 | ANXA1,AQP5,BCL2A1,CA2,CEBPA,CSF2RA,DYNLT3,GSTA1,HCAR3,HSPA5,IL8,SFTPD,SPI1,TFAP2A | |||
| CRTC1 | −1.203 | 1.72E-02 | NQO1 | |||
| PYCARD | −1.136 | 4.23E-03 | IL18,IL8 | |||
| TFAP2A | −1.069 | 1.07E-04 | ANXA1,CEBPA,DCBLD2,LIPA,PLA2G16,PLAU,PLAUR,RAB27B | |||
| MYB | 1.017 | 1.33E-02 | CD34,IGFBP5,JUN,MYB,VIM | |||
| PHF1 | 1.215 | 1.89E-05 | HOXA10,HOXA11,HOXA9,HOXD10,HOXD9 | |||
| HOXA5 | 1.317 | 9.92E-03 | PGR,PTN,TP53 | |||
| HOXA10 | 1.546 | 3.64E-03 | AQP1,EMX2,HOXA11,HOXA5,HSP90AA1,IGFBP5,MEIS2,MFNG,PDPN, PIK3R1,PROS1 | |||
| HOXA11 | 2.81 | 3.26E-03 | HOXA11,SIX2,ZNF192 | |||
| TBX3 | 3.031 | 2.26E-02 | SMPX,TP53 | |||
| LR7>LR3 | FOS | Activated | 2.588 | 3.34E-03 | BCAR3,CD164,CFLAR,COL1A1,FLRT2,FZD5,GAS2,GSK3B,GSR,HSD17B10, IKBKAP,LGALS3BP,LTBP2,NCF2,NFIL3,PCYT2,PFN1,PIAS1,PLD1,SMAD5, IPARP,YWHAZ | |
| MYCN | Activated | 2.410 | 5.60E-01 | CAV1,COL1A1,PDIA4,XRCC3,ZYX | ||
| TP53 | Inhibited | −2.061 | 4.24E-03 | AKAP12,AKT1,APC,APP,BTG2,CAV1,CFLAR,COL1A1,DDB2,EIF4G3,ENPP2,FLRT2,GSK3B,GSR,IRF7,MAPK1,MBNL2,MED13L,MUC2,MX1,NFKBIA,PLEKHB2,POLR3E,PPP1CC,PPP5C,PROSC,PSEN1,RFWD2,SH3BGRL2, SHC1,SPHK1,SREBF1,TAGLN2,TFPI2,TMEM97,VCL,ZYX | ||
| LR3>LR7 | CEBPA | Inhibited | −2.445 | 1.90E-02 | ARHGEF5,CEBPD,F9,ITGB5,LCK,MYF6,NR4A2,PLOD2,PTPRC,TBXAS1, THBD,VDR | |
| IKZF1 | 1.451 | 3.46E-03 | CYP2J2,FGFR1,LCK,MLL,NOTCH1,NOTCH3,UACA | |||
| NR3C1 | 1.603 | 8.63E-03 | BCL2L11,BHLHE40,BMF,BRWD1,CXCL11,DNAJC15,DUT,ENC1,FN1,NR3C1,PAWR,PHF17,PPP3CC,PRPF40A,PTP4A2,RBMS2,STAT3,STAT5A,THBD, UNC13B | |||
| EZH2 | 1.647 | 2.54E-04 | ANXA6,BCL2L11,CDK6,CSNK1A1,CXCL11,EZH2,IKZF1,LYPD6B,RBM5, SATB1,TRIM38 | |||
| SREBF1 | −2.24 | 6.91E-04 | ACSL1,AK4,CYB5A,DARS,GSR,IDH1,NCF2,RDH11,SREBF1,STAR,TM7SF2, TMEM97 | |||
| PPARGC1A | −1.933 | 3.11E-02 | DLAT,ESRRA,NDUFS1,PPARGC1A,SDHA,SREBF1,TXN2 | |||
| ESRRA | −1.373 | 4.65E-02 | ACSL1,CYB5A,CYC1,ESRRA,PPARGC1A,SIRT1 |
z-score indications significance of prediction of activation status of the respective transcription factor; it is predicted to be activated at z-score ≥2 or inhibited at z-score ≤−2:
overlap p-value: indicates significance of the association between the respective transcription factor and the predicated target genes showing differential expression in the experiment; threshold p≤5.0E-02.
Figure 3Target genes of TP53 as predicted by IPA.